Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 2/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38655453 | 1.00 | NPSR1 (0.61) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL29459459 | 1.00 | NPSR1 (0.61) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL28923858 | 0.93 | NPSR1 (0.54) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL28165914 | 0.90 | NPSR1 (0.51) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Podofilox SCHEMBL29363143 | 0.89 | LMNA (0.77) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Podofilox SCHEMBL27708556 | 0.89 | LMNA (0.77) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL20977542 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Ethyl Picropodophyllate SCHEMBL27895488 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL12964076 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL9131949 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21642 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001080884-A1 | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000054795-A1 | COMBINED THERAPY WITH A CHEMOTHERAPEUTIC AGENT AND AN ONCOLYTIC VIRUS FOR KILLING TUMOR CELLS IN A SUBJECT | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |